Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research

Abstract

The product of the ABCB1 gene, P-glycoprotein (PGP), is a transmembrane active efflux pump for a variety of drugs. It is a putative mechanism of multidrug resistance in a range of diseases. It is postulated that ABCB1 polymorphisms contribute to variability in PGP function, and that therefore multidrug resistance is, at least in part, genetically determined. However, studies of ABCB1 genotype or haplotype and PGP expression, activity or drug response have produced inconsistent results. This critical review of ABCB1 genotype and PGP function, including mRNA expression, PGP–substrate drug pharmacokinetics and drug response, highlights methodological limitations of existing studies, including inadequate power, potential confounding by co-morbidity and co-medication, multiple testing, poor definition of disease phenotype and outcomes, and analysis of multiple drugs that might not be PGP substrates. We have produced recommendations for future research that will aid clarification of the association between ABCB1 genotypes and factors related to PGP activity.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152–162.

    Article  CAS  PubMed  Google Scholar 

  2. Rosenberg MF, Callaghan R, Ford RC, Higgins CF . Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 1997; 272: 10685–10694.

    CAS  PubMed  Google Scholar 

  3. Sakaeda T, Nakamura T, Okumura K . Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4: 397–410.

    CAS  PubMed  Google Scholar 

  4. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–698.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I . Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–269.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988; 48: 1926–1929.

    CAS  PubMed  Google Scholar 

  7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC . Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735–7738.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Tanigawara Y . Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137–140.

    CAS  PubMed  Google Scholar 

  9. Watkins PB . The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161–170.

    CAS  PubMed  Google Scholar 

  10. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von RO, Zundler J et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–153.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Cmejlova J, Hildinger M, Cmejla R, Fuchs O, Kalabova D, Baum C et al. Impact of splice-site mutations of the human MDR1 cDNA on its stability and expression following retroviral gene transfer. Gene Therapy 2003; 10: 1061–1065.

    CAS  PubMed  Google Scholar 

  12. Zhao Z, Sheps JA, Ling V, Fang LL, Baillie DL . Expression analysis of ABC transporters reveals differential functions of tandemly duplicated genes in Caenorhabditis elegans. J Mol Biol 2004; 344: 409–417.

    CAS  PubMed  Google Scholar 

  13. Hoffmeyer S, Burk O, von RO, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W . Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genom 2005; 15: 693–704.

    CAS  Google Scholar 

  15. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53: 526–534.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Hitzl M, Drescher S, van der KH, Schaffeler E, Fischer J, Schwab M et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293–298.

    CAS  PubMed  Google Scholar 

  17. Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M et al. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004; 14: 309–318.

    CAS  PubMed  Google Scholar 

  18. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30–36.

    CAS  PubMed  Google Scholar 

  19. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002; 25: 1356–1359.

    CAS  PubMed  Google Scholar 

  20. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297–303.

    CAS  PubMed  Google Scholar 

  21. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451–457.

    CAS  PubMed  Google Scholar 

  22. Meissner K, Jedlitschky G, Meyer zu SH, Dazert P, Eckel L, Vogelgesang S et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004; 14: 381–385.

    CAS  PubMed  Google Scholar 

  23. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M . Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 2005; 59: 365–370.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572–583.

    CAS  PubMed  Google Scholar 

  25. Uwai Y, Masuda S, Goto M, Motohashi H, Saito H, Okuda M et al. Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J Hum Genet 2004; 49: 40–45.

    CAS  PubMed  Google Scholar 

  26. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137–1143.

    CAS  PubMed  Google Scholar 

  27. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189–199.

    CAS  PubMed  Google Scholar 

  28. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM . Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62: 1–6.

    CAS  PubMed  Google Scholar 

  29. Morita N, Yasumori T, Nakayama K . Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 2003; 65: 1843–1852.

    CAS  PubMed  Google Scholar 

  30. Lin JH . Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55: 53–81.

    CAS  PubMed  Google Scholar 

  31. Tang C, Lin JH, Lu AY . Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005; 33: 603–613.

    CAS  PubMed  Google Scholar 

  32. Jette L, Beaulieu E, Leclerc JM, Beliveau R . Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 1996; 270: F756–F765.

    CAS  PubMed  Google Scholar 

  33. Lazarowski AJ, Garcia Rivello HJ, Vera Janavel GL, Cuniberti LA, Cabeza Meckert PM, Yannarelli GG et al. Cardiomyocytes of chronically ischemic pig hearts express the MDR-1 gene-encoded P-glycoprotein. J Histochem Cytochem 2005; 53: 845–850.

    CAS  PubMed  Google Scholar 

  34. Buyse M, Radeva G, Bado A, Farinotti R . Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 2005; 69: 1745–1754.

    CAS  PubMed  Google Scholar 

  35. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003; 73: 1282–1292.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809–812.

    CAS  PubMed  Google Scholar 

  37. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584–594.

    CAS  PubMed  Google Scholar 

  38. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400–1404.

    CAS  PubMed  Google Scholar 

  39. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 311–316.

    CAS  PubMed  Google Scholar 

  40. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610–616.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209–219.

    CAS  PubMed  Google Scholar 

  42. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002; 63: 765–770.

    CAS  PubMed  Google Scholar 

  43. Haufroid V, Mourad M, Van KV, Wawrzyniak J, De MM, Eddour DC et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–154.

    CAS  PubMed  Google Scholar 

  44. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW . No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47: 1048–1052.

    CAS  PubMed  Google Scholar 

  45. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37: 1730–1732.

    CAS  PubMed  Google Scholar 

  46. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182–1187.

    CAS  PubMed  Google Scholar 

  47. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004; 58: 548–553.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Min DI, Ellingrod VL . C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002; 24: 400–404.

    CAS  PubMed  Google Scholar 

  49. Anglicheau D, Le CD, Lechaton S, Laurent-Puig P, Kreis H, Beaune P et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595–603.

    CAS  PubMed  Google Scholar 

  50. Hesselink DA, van GT, van Schaik RH, Balk AH, van dH I, van DT et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545–556.

    CAS  PubMed  Google Scholar 

  51. Kuzuya T, Kobayashi T, Moriyama N, Nagasaka T, Yokoyama I, Uchida K et al. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 2003; 76: 865–868.

    CAS  PubMed  Google Scholar 

  52. Singh D, Alexander J, Owen A, Rustom R, Bone M, Hammad A et al. Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation 2004; 77: 557–561.

    CAS  PubMed  Google Scholar 

  53. Anglicheau D, Thervet E, Etienne I, Hurault De LB, Le MY, Touchard G et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422–433.

    CAS  PubMed  Google Scholar 

  54. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004; 78: 21–25.

    CAS  PubMed  Google Scholar 

  55. Zheng H, Schuetz E, Zeevi A, Zhang J, McCurry K, Webber S et al. Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol 2005; 45: 404–410.

    CAS  PubMed  Google Scholar 

  56. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486–1489.

    CAS  PubMed  Google Scholar 

  57. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555–564.

    CAS  PubMed  Google Scholar 

  58. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ . Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89–95.

    CAS  PubMed  Google Scholar 

  59. Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL . No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003; 74: 487–498.

    CAS  PubMed  Google Scholar 

  60. Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R, Roots I . MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fund Clin Pharmacol 2003; 17: 463–469.

    CAS  Google Scholar 

  61. Plasschaert SL, Groninger E, Boezen M, Kema I, de Vries EG, Uges D et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004; 76: 220–229.

    CAS  PubMed  Google Scholar 

  62. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004; 76: 418–427.

    CAS  PubMed  Google Scholar 

  63. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003; 13: 741–757.

    CAS  PubMed  Google Scholar 

  64. Zhou Q, Sparreboom A, Tan EH, Cheung YB, Lee A, Poon D et al. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol 2005; 59: 415–424.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genom 2005; 15: 599–608.

    CAS  Google Scholar 

  66. Romiti N, Tramonti G, Donati A, Chieli E . Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci 2004; 76: 293–302.

    CAS  PubMed  Google Scholar 

  67. Freimer NB, Sabatti C . Guidelines for association studies in Human Molecular Genetics. Hum Mol Genet 2005; 14: 2481–2483.

    CAS  PubMed  Google Scholar 

  68. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661–674.

    CAS  PubMed  Google Scholar 

  69. Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004; 44: 135–140.

    CAS  PubMed  Google Scholar 

  70. Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J . P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol 2004; 31: 758–763.

    CAS  PubMed  Google Scholar 

  71. Kotrych K, Domanski L, Gornik W, Drozdzik M . MDR1 gene polymorphism in allogenic kidney transplant patients with tremor. Pharmacol Rep 2005; 57: 241–245.

    PubMed  Google Scholar 

  72. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002; 74: 571–572.

    CAS  PubMed  Google Scholar 

  73. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 2003; 13: 675–682.

    CAS  PubMed  Google Scholar 

  74. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA . A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenom J 2002; 2: 191–196.

    CAS  Google Scholar 

  75. De Luca V, Mundo E, Trakalo J, Wong GW, Kennedy JL . Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenom J 2003; 3: 297–299.

    CAS  Google Scholar 

  76. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003; 17: 1696–1698.

    PubMed  Google Scholar 

  77. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003; 17: 201–208.

    CAS  PubMed  Google Scholar 

  78. Alonso-Villaverde C, Coll B, Gomez F, Parra S, Camps J, Joven J et al. The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS 2005; 19: 341–342.

    CAS  PubMed  Google Scholar 

  79. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005; 19: 371–380.

    CAS  PubMed  Google Scholar 

  80. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005; 192: 1931–1942.

    CAS  PubMed  Google Scholar 

  81. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442–1448.

    CAS  PubMed  Google Scholar 

  82. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63: 1090–1092.

    CAS  PubMed  Google Scholar 

  83. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004; 63: 1087–1089.

    CAS  PubMed  Google Scholar 

  84. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005; 46: 643–647.

    CAS  PubMed  Google Scholar 

  85. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. Seizure 2006; 15: 67–72.

    PubMed  Google Scholar 

  86. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH . Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 2005; 6: 411–417.

    CAS  PubMed  Google Scholar 

  87. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J . HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132: 1183–1192.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ . Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004; 93: 1046–1050.

    CAS  PubMed  Google Scholar 

  89. Bercovich D, Friedlander Y, Korem S, Houminer A, Hoffman A, Kleinberg L et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 2006; 185: 97–107.

    CAS  PubMed  Google Scholar 

  90. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenom J 2005; 5: 352–358.

    CAS  Google Scholar 

  91. Knutsen T, Mickley LA, Ried T, Green ED, du MS, Schrock E et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998; 23: 44–54.

    CAS  PubMed  Google Scholar 

  92. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A . Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005; 24: 8061–8075.

    CAS  PubMed  Google Scholar 

  93. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998; 92: 4296–4307.

    CAS  PubMed  Google Scholar 

  94. Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M et al. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 1999; 262: 924–932.

    CAS  PubMed  Google Scholar 

  95. Ma JF, Grant G, Staelens B, Howard DL, Melera PW . In vitro translation of a 2.3-kb splicing variant of the hamster pgp1 gene whose presence in transfectants is associated with decreased drug resistance. Cancer Chemother Pharmacol 1999; 43: 19–28.

    CAS  PubMed  Google Scholar 

  96. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62: 4955–4962.

    CAS  PubMed  Google Scholar 

  97. Nishioka C, Sakaeda T, Nakamura T, Moriya Y, Okamura N, Tamura T et al. MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci 2004; 50: 181–188.

    CAS  PubMed  Google Scholar 

  98. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314–321.

    CAS  PubMed  Google Scholar 

  99. Kaya P, Gunduz U, Arpaci F, Ural AU, Guran S . Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol 2005; 80: 26–34.

    CAS  PubMed  Google Scholar 

  100. Wilson JF, Weale ME, Smith AC, Gratrix F, Fletcher B, Thomas MG et al. Population genetic structure of variable drug response. Nat Genet 2001; 29: 265–269.

    CAS  PubMed  Google Scholar 

  101. Pritchard JK, Rosenberg NA . Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220–228.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Hoggart CJ, Parra EJ, Shriver MD, Bonilla C, Kittles RA, Clayton DG et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet 2003; 72: 1492–1504.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Ardlie KG, Lunetta KL, Seielstad M . Testing for population subdivision and association in four case-control studies. Am J Hum Genet 2002; 71: 304–311.

    CAS  PubMed  PubMed Central  Google Scholar 

  104. Turakulov R, Easteal S . Number of SNPS loci needed to detect population structure. Hum Hered 2003; 55: 37–45.

    PubMed  Google Scholar 

  105. Reich DE, Goldstein DB . Detecting association in a case–control study while correcting for population stratification. Genet Epidemiol 2001; 20: 4–16.

    CAS  PubMed  Google Scholar 

  106. Pritchard JK, Stephens M, Donnelly P . Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945–959.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, Coffey AJ et al. Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genom 2006; 16: 439–450.

    CAS  Google Scholar 

  108. Lynch M, Walsh B . Genetics and Analysis of Quantitative Traits. Sinauer Associates Incorporated: Sunderland, 1997.

    Google Scholar 

  109. Holm S . A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65–70.

    Google Scholar 

  110. Churchill GA, Doerge RW . Empirical threshold values for quantitative trait mapping. Genetics 1994; 138: 963–971.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Dudbridge F, Gusnanto A, Koeleman BP . Detecting multiple associations in genome-wide studies. Hum Genom 2006; 2: 310–317.

    CAS  Google Scholar 

  112. Storey JD, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440–9445.

    CAS  PubMed  PubMed Central  Google Scholar 

  113. Colhoun HM, McKeigue PM, Davey SG . Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865–872.

    PubMed  Google Scholar 

  114. Terwilliger JD, Goring HHH, Magnusson PKE, Lee JH . Study design for genetic epidemiology and gene mapping: the Korean diaspora project. Life Sci Res 2002; 6: 95–115.

    Google Scholar 

  115. Sham PC, Cherny SS, Purcell S, Hewitt JK . Power of linkage versus association analysis of quantitative traits, by use of variance-components models, for sibship data. Am J Hum Genet 2000; 66: 1616–1630.

    CAS  PubMed  PubMed Central  Google Scholar 

  116. Knight J . A survey of current software for genetic power calculations. Hum Genom 2004; 1: 225–227.

    CAS  Google Scholar 

  117. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK . Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001; 51: 345–349.

    CAS  PubMed  PubMed Central  Google Scholar 

  118. Potschka H, Fedrowitz M, Loscher W . P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001; 12: 3557–3560.

    CAS  PubMed  Google Scholar 

  119. Maines LW, Antonetti DA, Wolpert EB, Smith CD . Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 2005; 49: 610–617.

    CAS  PubMed  Google Scholar 

  120. Rothman KJ, Greenland S . Modern Epidemiology. Lippincott-Raven: Philadelphia, 1998.

    Google Scholar 

  121. Cardon LR, Bell JI . Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91–99.

    CAS  PubMed  Google Scholar 

  122. Reich DE, Lander ES . On the allelic spectrum of human disease. Trends Genet 2001; 17: 502–510.

    CAS  PubMed  Google Scholar 

  123. Schork NJ . Genetics of complex disease: approaches, problems, and solutions. Am J Respir Crit Care Med 1997; 156: S103–S109.

    CAS  PubMed  Google Scholar 

  124. Terwilliger JD, Weiss KM . Linkage disequilibrium mapping of complex disease: fantasy or reality? Curr Opin Biotechnol 1998; 9: 578–594.

    CAS  PubMed  Google Scholar 

  125. Risch N, Merikangas K . The future of genetic studies of complex human diseases. Science 1996; 273: 1516–1517.

    CAS  PubMed  Google Scholar 

  126. Clayton D, McKeigue PM . Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001; 358: 1356–1360.

    CAS  PubMed  Google Scholar 

  127. Setakis E, Stirnadel H, Balding DJ . Logistic regression protects against population structure in genetic association studies. Genome Res 2006; 16: 290–296.

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Terwilliger JD, Hiekkalinna T . An utter refutation of the ‘Fundamental Theorem of the HapMap’. Eur J Hum Genet 2006; 14: 426–437.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the Wellcome Trust for their support, and the reviewers for their constructive reviews and helpful comments. GL is supported in part by a Neurology Entry/Exit Scholarship from the Guarantors of Brain.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G D Leschziner.

Additional information

Duality of Interest

No conflicts of interest are declared.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leschziner, G., Andrew, T., Pirmohamed, M. et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7, 154–179 (2007). https://doi.org/10.1038/sj.tpj.6500413

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500413

Keywords

This article is cited by

Search

Quick links